Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

BPC-157 vs KPV

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Verdict: it depends on the goal

Neither BPC-157 nor KPV has a controlled human trial, so neither is proven for gut or tissue healing in people. Neither is FDA approved or on the 503A bulks list, but both are among the six peptides covered by HHS's October 28, 2026 draft enforcement discretion policy for single-ingredient compounding on a patient-specific prescription, with different allowed routes (KPV only topical or oral). For both, FDA's drug center recommended against listing and the advisory committee voted in favor (HHS policy, Appendix B). The difference is focus: KPV is an anti-inflammatory fragment of alpha-MSH tested in mouse colitis, while BPC-157 is a gastric peptide fragment tested mostly in rat tendon, muscle, and gut injury.

Verified: Verified Oct 28, 2026
BPC-157 oralSponsoredFrom Bodybuilding Peptides

Which is better, BPC-157 or KPV?

The two share the same evidence grade (animal only) and the same draft HHS enforcement discretion status, and both are prohibited in sport, so neither wins on the criteria that matter most. For intestinal inflammation, KPV has two independent 2008 mouse colitis studies with a defined uptake mechanism (PepT1); for tendon or musculoskeletal injury, BPC-157 has the more relevant rodent data, though mostly from one research group. The choice depends on the problem, and in both cases standard medical care should come first because no human data exist. [1] [2] [3] [4] [5] [6] [12]

How do BPC-157 and KPV compare?

BPC-157 and KPV compared by dimension
DimensionBPC-157KPV
What it is [1] [7]Synthetic 15 amino acid fragment of a gastric protein (body protection compound).Synthetic tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-melanocyte stimulating hormone.
Proposed mechanism [1] [2] [8]Growth factor receptor upregulation, nitric oxide system modulation, and VEGFR2 driven angiogenesis in animal and cell models.Taken into gut epithelial and immune cells by the PepT1 transporter, then inhibits NF-kB and MAP kinase signaling and cytokine release. Works without the MC1 receptor and does not cause pigmentation.
Main animal evidence [1] [2] [4] [7]Rat Achilles tendon transection healed faster with more fibroblast outgrowth and migration; rodent studies report healing of NSAID ulcers, fistulas, and anastomoses.Oral KPV reduced DSS and TNBS colitis in mice; a second lab found faster recovery, weight regain, and less inflammation in DSS and T cell transfer colitis.
Independence of the research base [1] [2] [3]Mostly a small number of laboratories, largely in Zagreb, with limited independent replication.Two independent laboratories published consistent mouse colitis results in 2008; the total body of work is small.
Human evidence [1] [3] [10]No controlled human trial. Three small uncontrolled pilot reports from one clinic (knee pain, interstitial cystitis, and intravenous safety) reported benefit or no adverse events but had no comparison group.No indexed human trial for any indication.
Theoretical safety concern [1] [8]Promotes angiogenesis in animals, so a theoretical concern about growth of existing tumors has been raised (not shown in humans).Dampens NF-kB driven immune signaling, so a theoretical concern about impaired response to infection has been raised (not shown in humans).
FDA and compounding status [5] [6] [12] [13]Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (subcutaneous, intramuscular, oral, or topical) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. Covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding it as a single-ingredient product (topical or oral only) on a patient-specific prescription, if sourcing, testing, and adverse event reporting conditions are met. The draft is not binding and may be revisited. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B).
Note: Same draft policy for both, with different allowed routes. Neither is FDA approved, and the draft policy does not mention 503B outsourcing facilities.
WADA status [9]Prohibited at all times under S0 (non-approved substances).Prohibited at all times under S0 (non-approved substances).
Typical cost [5] [11] [12]No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price.No verified compounded price yet: HHS's draft enforcement discretion policy was only announced on October 28, 2026, and advertised clinic prices are not a comparable price. The draft policy covers only topical and oral KPV, so injectable KPV is not covered.
Note: Products sold as research chemicals for human use are unapproved drugs and are not verified for identity or purity.

Evidence grade and regulatory status

Pulled from each peptide’s own record, so it stays in step with the peptide pages.

BPC-157 and KPV: grade, status, and cost
AttributeBPC-157KPV
ClassSynthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compoundSynthetic tripeptide (lysine-proline-valine), the C-terminal fragment of alpha-melanocyte stimulating hormone (alpha-MSH)
What it isA 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a draft HHS compounding policy from October 2026.Anti-inflammatory fragment of the hormone alpha-MSH; mouse colitis data, no human trial; topical and oral use in HHS's October 2026 draft policy.
EvidenceEvidence: Animal-only evidenceEvidence: Animal-only evidence
FDA statusRegulatory: HHS interim policy (draft)Regulatory: HHS interim policy (draft)
CompoundingBPC-157 is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds BPC-157 when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (subcutaneous, intramuscular, oral, or topical), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add BPC-157 to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.KPV is not an FDA approved drug. It was in 503A Category 2 (substances that may raise significant safety risks) from September 2023 until April 22, 2026, when its nomination was withdrawn and FDA moved it to its list of withdrawn nominations. FDA still presented it to the Pharmacy Compounding Advisory Committee on July 23, 2026: FDA's drug center (CDER) recommended against adding it to the 503A bulks list, and the committee voted in favor (HHS policy, Appendix B). On October 28, 2026, HHS released a draft enforcement discretion policy (FR Doc. 2026-22192, published in the Federal Register on October 30, 2026). Under it, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician that compounds KPV when every condition is met: a single active ingredient only (no blends or stacks), an allowed route (topical or oral only), a patient-specific prescription, bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting HHS's testing standard, and reporting of serious adverse events to FDA. Oral forms also need documentation that the formulation is adequately absorbed by mouth in humans. The draft policy is not an FDA approval, does not add KPV to the 503A bulks list, is not binding, and HHS may revisit it. Comments are open through November 13, 2026. The policy does not mention 503B outsourcing facilities. State law still applies, and products sold as research use only for human use are still unapproved drugs.
WADAWADA: WADA prohibitedWADA: WADA prohibited
RoutesSubcutaneous injection (as sold), Oral capsule (as sold), Intraperitoneal, oral in water, and topical (animal studies)Oral capsule (as sold), Subcutaneous injection (as sold), Topical cream and nasal spray (as sold), Oral in drinking water and intraperitoneal (mouse studies)
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient KPV on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Last verified

Has BPC-157 been tested directly against KPV?

No published trial has compared BPC-157 and KPV directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.

What do BPC-157 and KPV cost?

Typical cost of BPC-157 and KPV
DimensionBPC-157KPV
Typical costNo FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient BPC-157 on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.No FDA approved product and no verified compounded price. Under HHS's October 2026 draft enforcement discretion policy, HHS says it does not intend to take enforcement action against a licensed pharmacy that compounds single-ingredient KPV on a patient-specific prescription under strict conditions, but PeptideAgent has no verified price for that yet. Advertised clinic prices are not a comparable price. Products sold as research chemicals for human use are still unapproved drugs and are not verified for identity or purity.
Price detailBPC-157 price by channelKPV price by channel

Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.

What's actually offered, what that means for you, and what to check if you're going ahead anyway: see the BPC-157 page and the KPV page.

Are BPC-157 and KPV combined?

BPC-157 and KPV are sold together in the premixed blend below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend page covers what is in each product, the evidence for each ingredient, and legal status.

  • KLOW: No federal basis to compound.

Frequently asked questions

Which is better for gut inflammation or IBD, BPC-157 or KPV?

Neither has been tested in people with inflammatory bowel disease. KPV has two independent mouse colitis studies showing less inflammation and faster recovery; BPC-157 has rodent data on ulcers, fistulas, and NSAID injury. Approved IBD treatments with human trial data remain the standard. [1] [2] [7]

Does KPV cause tanning like other alpha-MSH peptides?

No. KPV is only the last three amino acids of alpha-MSH, and in mice its anti-inflammatory effect did not depend on the MC1 receptor that drives pigmentation. [2]

Can a pharmacy compound BPC-157 or KPV?

Possibly, under conditions. Neither is on the 503A bulks list, but both are covered by HHS's October 28, 2026 draft enforcement discretion policy: HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility, or licensed physician compounding either one as a single-ingredient product on a patient-specific prescription, by an allowed route (BPC-157: subcutaneous, intramuscular, oral, or topical; KPV: topical or oral only), from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. A combined BPC-157 and KPV product is not covered. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). The policy is a draft, not an FDA approval or a 503A bulks listing, is not binding, and may be revisited; the notice was published in the Federal Register on October 30, 2026, and comments are open through November 13, 2026. State law still applies. [5] [6] [12] [13]

Are BPC-157 and KPV allowed in sport?

No. Both are prohibited at all times under S0 of the WADA Prohibited List as non-approved substances. [9]

Has either one been studied in people?

Not in a controlled trial. KPV has no published human study of any kind. BPC-157 has three small uncontrolled pilot reports from one clinic, none of which tested gut disease. Neither has a human dose finding study, so dose figures circulating online come from animal work or sellers, not from human data. [1] [10]

Conditions studied

From the blog

Sources

Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.

  1. [1]Dalmasso G et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology 2008PubMed 18061177, 2008
  2. [2]Kannengiesser K et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis 2008PubMed 18092346, 2008
  3. [3]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
  4. [4]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
  5. [5]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
  6. [6]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
  7. [7]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
  8. [8]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (Curr Neuropharmacol 2016)PubMed 27138887, 2016
  9. [9]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  10. [10]McGuire FP et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025PubMed 40789979, 2025

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). BPC-157 vs KPV: evidence, cost, and legality. https://peptideagent.ai/compare/bpc-157-vs-kpv
HTML link
<a href="https://peptideagent.ai/compare/bpc-157-vs-kpv">BPC-157 vs KPV: evidence, cost, and legality</a>, PeptideAgent, updated October 28, 2026.